Domestic PD-1 first half results are very public! It is expected to exceed 7 billion yuan for the full year.

Recently, the major pharmaceutical companies have announced the first half of 2020 results, several domestic PD-1 sales have also been announced.
Junshi's Ripley Single Resistance in the first half of 2020 sales revenue of 426 million yuan, the current gross margin of 89.84 percent;
semi-annual report of Hengrui has not been published, even if the announcement will not disclose the specific variety of sales, but industry forecasts, Hengrui's Karelli Pearl single anti-first-half sales should be more than 2 billion yuan.
(Source: Annual Reports of Companies) PD-1 performance is mainly influenced by adaptation, price, marketing ability, in general, large adaptive disorders sell better than small adaptive disorders, in addition to price and strong sales capacity is also critical.
approved adaptive disease domestic PD-1 more to Hodgkin's lymphoma as the entry point to enter the market, and then in lung cancer, liver cancer and other large areas gradually landed.
although Terripley single resistance and Xindili single resistance occupy the first-hand advantage, but Hengrui Medicine and Baiji Shenzhou later came to the fore, the number of approved adaptive disorders has achieved anti-super.
Henrui PD-1 rides out dust in terms of the number and size of approved adaptive disorders.
in terms of quantity, at present, Hengrui's Karelli Pearl single resistance has been approved for 4 adaptive disorders, the most.
followed by Baiji Shenzhou's Tyreli Zhu single resistance, approved 2, Junshi's Ripley single resistance and Xindili single resistance were approved only 1 adaptive disorder.
in terms of size, Karelli Pearl Monoanti, Reilly Pearl Monoanti and Syndili Single Resistance were approved for third-line treatment of classic Hodgkin's lymphoma. in addition to
, Hengrui PD-1 has also been approved liver cell carcinoma, esophageal squamous cancer and non-squamous non-small cell lung cancer (NSCLC), these three are the incidence of the highest incidence of large-scale adaptation, and is also the first and only approved these three adaptations of the domestic PD-1, especially the second-line treatment of hepatocellular carcinoma and combined chemotherapy line treatment of non-scale NSCLC, will bring a huge market to Hengrui.
Tyeth Reilly pearl single resistance is currently the only approved urethra skin cancer this adaptive disease of domestic PD-1, and Junshi is currently the only approved melanoma this adaptation is relatively small, which is the main reason for relatively small sales.
Domestic has been approved (including reported production) domestic PD-1 (source: NMPA, annual report of the company, as of 2020.8.31) price point of view, domestic PD-1 single resistance in the first year cost of about 110,000 yuan, for imported varieties 1/2-1/3.
because Thyda's Xindilli monoanti is the only PD-1 single resistance that goes into health insurance, the price has an advantage.
addition, Junshi's Ripley single resistance price is the most popular, retail price of 7200 yuan / branch (240mg), PAP after the first year of the cost of 101,000 yuan, lower than other domestic varieties.
china has been approved PD-1 usage and treatment costs (source: company announcement, company official website) sales capacity In terms of sales capacity, Hengrui riding dust.
not only have the largest number of employees, but also the highest sales costs.
According to the 2019 annual report, Hengrui sales team of 14,686 people, sales costs of 8.625 billion yuan, as a leading domestic cancer drug enterprises, Hengrui for many years operating marketing channel energy is indisputable.
Junshi, Xinda, Baiji Shenzhou as a up-and-down show, sales capacity can be said to be in the same starting line, the gap is not large.
sales and marketing expenditure in the first half of 2020 was 447 million yuan, up 67.4% YoY, and the number of sales teams expanded to 1176.
and Junshi's 561-person sales team is responsible for the commercialization of Ripley monoanti and other drugs under study.
sales team in Shiji Shenzhou has also increased from just over 150 people at the time of the 2017 acquisition of The New Base (now owned by Shishi Shiguibao) in China to more than 900 at the end of 2019.
energy in the layout of the research adaptation determines the domestic PD-1 follow-up energy.
incidence of cancer in China is on the rise, and the number of new cancer patients will increase year by year.
among the high incidence of cancer, lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer ranked in the top five.
2018, the incidence of these five types of cancer together accounted for more than 50% of the overall incidence of cancer in China.
, lung cancer, colorectal cancer and esophageal cancer all had higher annual compound growth rates than other cancers.
increasing number of smokers in China and air pollution are risk factors for lung cancer, and the rise in colorectal and esophageal cancers is mainly linked to unhealthy eating habits.
(Source: Frost Sullivan Analysis) Due to epidemiological differences, the core adaptive disorders of domestic PD-1 monoantitor therapy differ from 8 overseas.
incidence of melanoma, which accounts for a large proportion overseas, is relatively low in China, while the proportion of liver cancer is significantly higher than that of overseas.
National adaptations showed four mostly small patterns, of which four solid tumor adaptations were non-small cell lung cancer (29%), esophageal cancer (24%), liver cancer (24%), stomach cancer (10%), and other adaptations included urethra cancer, nasopharyngeal cancer, small cell lung cancer, triple breast cancer, melanoma and lymphoma.
The competition for domestic PD-1 monoantigens in the field of major adaptive disorders has been fully launched, including 44 clinical trials of lung cancer (III. Phase 32), 22 clinical trials of liver cancer (III. Phase 13), and 66 clinical trials of urethra skin cancer (III.Phase 3).
China's domestic PD-1 mono-anti-China clinical progress (Source: Junshi Announcement) China's PD-1/L1 inhibitor market has experienced rapid growth, reaching RMB66.4 billion in 2023, with a compound growth rate of 133.5% from 2018 to 2023.
2018-2030E China PD-1/L1 market size and forecast (BILLION) (Source: Frost Sullivan Analysis) According to the domestic PD-1 half-year results forecast, 2020 domestic PD-1 annual sales will exceed 7 billion yuan, plus two imported PD-1, is expected to break through the 10 billion yuan mark, by now is definitely a historic moment.
.